United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine Rothblatt sold 3,833 shares of United Therapeutics Corp. stock on the open market in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $78.41, for a total transaction of $300,545.53. Following the completion of the transaction, the chief executive officer now directly owns 140 shares of the company’s stock, valued at approximately $10,977. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded down 0.23% on Friday, hitting $78.78. The stock had a trading volume of 35,195 shares. United Therapeutics Corp. has a 52 week low of $44.51 and a 52 week high of $79.95. The stock has a 50-day moving average of $74.65 and a 200-day moving average of $67.88. The company has a market cap of $3.933 billion and a P/E ratio of 13.62.
United Therapeutics Corp. (NASDAQ:UTHR) last announced its earnings results on Thursday, July 25th. The company reported $1.52 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.47 by $0.05. The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $250.17 million. During the same quarter in the prior year, the company posted $1.34 earnings per share. The company’s quarterly revenue was up 24.4% on a year-over-year basis.
UTHR has been the subject of a number of recent research reports. Analysts at Goldman Sachs Group Inc. raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $55.00 to $56.00 in a research note to investors on Wednesday, September 18th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics Corp. (NASDAQ:UTHR) in a research note to investors on Thursday, September 12th. They now have a $81.00 price target on the stock. Finally, analysts at Argus raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $75.00 to $85.00 in a research note to investors on Monday, August 5th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and one has given a buy rating to the stock. United Therapeutics Corp. currently has a consensus rating of “Hold” and a consensus price target of $64.20.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.